CI Photos / Shutterstock.com
As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.
Few areas of emerging research have generated as much excitement in the life sciences community as CRISPR/Cas9, a gene-editing system which relies on the cas9 enzyme to alter DNA. But who invented it and who owns it?
Life sciences experts are convinced by the revolutionary technology’s ability to put gene-editing at the heart of healthcare, making the associated IP an extremely valuable asset. Claims of ownership are far from resolved and have been the subject of protracted legal battles in the US and Europe.
An impending interference proceeding at the US Patent and Trademark Office (USPTO) will be critical in determining who lands the US rights to a key branch of the technology. There are few more qualified to shed some light on the matter than Eric Rhodes, chief executive officer of ERS Genomics.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
CRISPR/Cas9, ERS Genomics, gene-editing, DNA, ownership, USPTO, UC, patent rights, human medicine, R&D, Broad Institute, application, technology
